Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
A centralized support unit will be necessary for an envisioned patient registry-based clinical development platform, dubbed “clinical innovation network,” to provide one-stop services for drug makers to better utilize registered data, an industry leader said on April 7. Isao Teshirogi,…
To read the full story
Related Article
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds
April 20, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…